Multiple myeloma cells have greater phosphorylated Eg5 than hematopoietic cells. Eg5 phosphorylation increases microtubule binding and uniquely enhances BRD9876 activity. BRD9876 acts as an ATP- and ADP-competitive inhibitor with a…
Multiple myelomas (MM) is a plasma cell malignancy that accounts for approximately 10% of all hematological malignancies. Many new drugs and therapies apply to this disease, but it remains an…
Immunomodulatory agents (IMiDs) are a class of immunomodulatory drugs. Thalidomide analogs have induced significant antimyeloma effects via immune-modulation, antiangiogenesis, and antiproliferative effects. Specifically, identification of the mechanisms of resistance for…